Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions. New investor RA Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback